Log In
Print this Print this

BUPI, bupivacaine

  Manage Alerts
Collapse Summary General Information
Company Oracain ApS
DescriptionLozenge formulation of bupivacaine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat chronic pain; Treat oral mucositis (OM) pain induced by radiotherapy and/or chemotherapy in head and neck cancer patients
Regulatory Designation
PartnerMoberg Pharma AB

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today